Skip to content

A clinical trial for radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus

A clinical trial for radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019609
Enrollment
Unknown
Registered
2018-11-19
Start date
2018-12-01
Completion date
Unknown
Last updated
2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma with portal vein tumor thrombus

Interventions

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. patient aged 5 years to 80 years male or female; 2. patient was pathological or clinical diagnosed with hepatocellular carcinoma with portal vein tumor thrombus; surgical evaluation revealed that the primary lesion was unresectable and the patient had no distant metastasis; 3. According to PVTT, the patients with type II and III, that is, tumor thrombus involving the portal trunk and first grade branches; 4.Child-Pugh liver function rating: A or better B level (less than 8 points); 5. ECOG PS score: 0-2 6. Main organs are functioning normally,conform to the following criteria: (1) Blood tests: HB=90g/L; ANC=1.5×10^9/L; PLT=70×10^9/L; (2) Biochemical examination: ALB=28g/L; ALT?AST=5ULN; TBIL=1.5ULNd; Cr=1.5UL; 7. Participants voluntarily joined the study, signed informed consent, and had good compliance and follow-up.

Exclusion criteria

Exclusion criteria: 1. Poor physical condition, PS score 3-4; 2. Child-Pugh liver function rating: C level; 3. Huge tumors, hypersplenism, hepatic encephalopathy, massive ascites or extensive abdominal metastasis; 4. Active gastric ulcer and severe esophagogastric varices.

Design outcomes

Primary

MeasureTime frame
Over all survival (OS);

Secondary

MeasureTime frame
Objective Response Rate, ORR;Objective Response Rate, ORR;Disease control rate (DCR);Progression-free survival (PFS);Toxic and side effects;Quality of life (QOL);

Countries

China

Contacts

Public ContactXue Jun

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

xjunion@126.com+86 15071258754

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026